Development of the gene therapy technologies using adeno-associated virus (AAV)

使用腺相关病毒（AAV）的基因治疗技术的开发

基本信息

批准号：
12470203
负责人：
OZAWA Keiya
金额：
$ 9.34万
依托单位：
Jichi Medical School
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (B)
财政年份：
2000
资助国家：
日本
起止时间：
2000 至 2001
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-12470203/
关键词：
Gene therapy Gene transfer AAV vector packaging cell line AAVS1 locus Rep ITR TVI method

项目摘要

We studied the gene transfer methods using adeno-associated virus (AAV).1. Development of the method for AAV vector production: We developed novel packaging cell lines for AAV vector production by regulating the expression of cytotoxic AAV proteins through Cre/loxP system. First, we applied combined Cre/loxP system using variant loxP and wild-type loxP to the simultaneous regulation of Rep and Cap expressions. Second, we developed a novel 293-derived prepackaging cell line which constitutively expresses the antisense rep/cap driven by a loxP-flanked CMV promoter. This cell line was converted into a packaging cell line expressing Rep/Cap through the introduction of a Cre recombinase gene.2. Establishment and application of highly sensitive detection method for AAV vector-mediated transgenes : Long PCR (sometimes combined with nested PCR) was conducted with appropriate primer sets located on the D region of ITR. We also collected many samples from the experimental animals which received intramuscular injections of AAV vectors.3. Development of the method for targeted vector integration (TVI) into a defined locus on chromosome 19 using AAV-derived components (ITR and Rep gene) : 293 and K562 cells were transfected with the neoγ gene using the TVI method. We amplified junctional regions between cellular and transgene sequences by Alu-PCR. As a result, no cellular sequences regarded as a common recognition motif of the Rep proteins was found. We also developed mutant Rep-expression vectors with reduced cytotoxicity.

我们研究了使用腺相关病毒（AAV）的基因转移方法。 1. AAV载体生产方法的开发：我们通过Cre/loxP系统调节细胞毒性AAV蛋白的表达，开发了用于AAV载体生产的新型包装细胞系。首先，我们应用使用变体loxP和野生型loxP的组合Cre/loxP系统来同时调节Rep和Cap表达。其次，我们开发了一种新型的组成型表达的源自293的预包装细胞系。通过引入Cre重组酶基因将该细胞系转化为表达Rep/Cap的包装细胞系。2．AAV载体高灵敏检测方法的建立及应用。介导的转基因：使用位于 ITR D 区的适当引物组进行长 PCR（有时与巢式 PCR 结合），我们还从接受 AAV 肌肉注射的实验动物中收集了许多样本。 3.开发使用AAV衍生成分（ITR和Rep基因）将靶向载体整合（TVI）到19号染色体上的确定基因座的方法：使用TVI方法用neoγ基因转染293和K562细胞。通过 Alu-PCR 扩增了细胞和转基因序列之间的连接区域，结果，没有发现被视为 Rep 蛋白的共同识别基序的细胞序列。细胞毒性。